By Neuroscience News
Semaglutide, known as Ozempic/Wegovy, does not negatively impact brain health and is associated with a lower risk of cognitive problems and less nicotine dependence, according to a new study.
Researchers found no increased risk of adverse neurological or psychiatric outcomes compared to other antidiabetic medications.
The study analyzed over 100 million patient records in the USA, including more than 20,000 people taking semaglutide.
The study found that semaglutide was not associated with an increased risk of neurological and psychiatric conditions such as dementia, depression, or anxiety.
Semaglutide was associated with a lower risk of cognitive problems and nicotine dependence, suggesting benefits beyond diabetes management.
Researchers emphasized the potential public health implications, including reducing cognitive deficits and smoking rates among patients with diabetes.
Despite the robust methodology and extensive data, further investigation is needed to understand how semaglutide has these effects.
The findings apply to diabetes patients and highlight the importance of replicating the results in a randomized controlled trial for broader application.